Jul. 30 at 2:06 PM
🚨 Biotech earnings season has begun!
Q2/H1 2025 results are rolling in 🧬
European companies dominate early reports — but a few US names are worth watching too.
📊 For investors:
Here’s a sharp summary of revenue, cash, burn, and what’s next in the clinic. Dive in 👇
uniQure
$QURE 🇳🇱
• Q2 revenue:
$5.3M (–52%)
• Q2 net loss: –
$37.7M
• Cash:
$377M – runway into H2 2027
🧬 AMT-130 granted FDA Breakthrough Designation
📄 BLA submission planned Q1 2026
Novo Nordisk
$NVO 🇩🇰
• Q2 sales: +18%
⚠️ 2025 guidance revised:
• Sales: 8–14% (was 13–21%)
• EBIT: 10–16% (was 16–24%)
📉 Due to softer Wegovy/Ozempic demand in the US
Cardiff Oncology
$CRDF 🇺🇸
• Q2 revenue:
$121K
• Q2 net loss: –
$13.9M
• Cash:
$71M – runway into Q1 2027
📉 Focused on cutting burn rate
Repligen
$RGEN 🇺🇸
• Q2 revenue:
$182.4M (+15% YoY)
• Cash:
$709M
📊 2025 guidance:
• Revenue:
$715–735M
• Sales growth expected: +20% YoY
